The CHOPAN registry aims to collect real-time data on pregnant women who are infected with the coronavirus that causes COVID-19 (SARS-CoV2) to improve our understanding of its impact on pregnancy outcomes. This registry will provide regular feedback to clinicians and public health officials to allow evidence-based management of women and their babies with coronavirus infection.
This registry was developed by Australian clinicians in collaboration with international colleagues in order to maximise its value to the global community.
The aims of the registry are to:
1. Describe the presentation and clinical course of coronavirus infection in pregnant women
2. Assess obstetric, perinatal and neonatal outcomes after coronavirus infection
3. Describe modes of transmission, including any cases of mother-to-child transmission
4. Identify any factors that influence disease outcome for mother and baby including: timing and mode of delivery, breastfeeding, rooming-in/separation, the use of anti-viral treatments and supportive therapies
5. Facilitate international collaborative efforts to improve care of women exposed to novel and emergent pathogens.
This study is registered with the Australian and New Zealand Clinical Trials Registry #ACTRN12620000449932 and has the support of the Australian and New Zealand College of Obstetricians and Gynaecologists.
It has received approval from the Human Research Ethics Committees of Monash Health under the National Mutual Acceptance Scheme (#RES-20-0000-215A).
Strict provisions are in place to protect the privacy of individuals in the registry. Women may opt out of the registry if they wish.